Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy lepodisiran and the expansion of their digital healthcare platform, ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.